{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(8)"],"submitter":["Sharma M"],"pubmed_abstract":["Mesenchymal stem cell (MSC) extracellular vesicles (EVs) have beneficial effects in preclinical bronchopulmonary dysplasia and pulmonary hypertension (BPD-PH) models. The optimal source, dosing, route, and duration of effects are however unknown. The objectives of this study were to (a) compare the efficacy of GMP-grade EVs obtained from Wharton's Jelly MSCs (WJ-MSCs) and bone marrow (BM-MSCs), (b) determine the optimal dosing and route of administration, (c) evaluate its long-term effects, and (d) determine how MSC EVs alter the lung transcriptome. Newborn rats exposed to normoxia or hyperoxia (85% O2) from postnatal day (P)1-P14 were given (a) intra-tracheal (IT) BM or WJ-MSC EVs or placebo, (b) varying doses of IT WJ-MSC EVs, or (c) IT or intravenous (IV) WJ-MSC EVs on P3. Rats were eva"],"journal":["Stem cells translational medicine"],"pagination":["828-840"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9397655"],"repository":["biostudies-literature"],"pubmed_title":["Mesenchymal Stem Cell-derived Extracellular Vesicles Prevent Experimental Bronchopulmonary Dysplasia Complicated By Pulmonary Hypertension."],"pmcid":["PMC9397655"],"pubmed_authors":["Chang L","Sterling S","Chen P","Aguilar-Caballero D","Huang J","Williams K","Schmidt A","Bellio MA","Khan A","Zambrano R","Hare JM","Kulandavelu S","Damianos A","Sharma M","Janjindamai C","Benny M","Batlahally S","Wu S","Kelly K","Young K","Han C","Chen S"],"additional_accession":[]},"is_claimable":false,"name":"Mesenchymal Stem Cell-derived Extracellular Vesicles Prevent Experimental Bronchopulmonary Dysplasia Complicated By Pulmonary Hypertension.","description":"Mesenchymal stem cell (MSC) extracellular vesicles (EVs) have beneficial effects in preclinical bronchopulmonary dysplasia and pulmonary hypertension (BPD-PH) models. The optimal source, dosing, route, and duration of effects are however unknown. The objectives of this study were to (a) compare the efficacy of GMP-grade EVs obtained from Wharton's Jelly MSCs (WJ-MSCs) and bone marrow (BM-MSCs), (b) determine the optimal dosing and route of administration, (c) evaluate its long-term effects, and (d) determine how MSC EVs alter the lung transcriptome. Newborn rats exposed to normoxia or hyperoxia (85% O2) from postnatal day (P)1-P14 were given (a) intra-tracheal (IT) BM or WJ-MSC EVs or placebo, (b) varying doses of IT WJ-MSC EVs, or (c) IT or intravenous (IV) WJ-MSC EVs on P3. Rats were eva","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-19T09:29:39.032Z","creation":"2025-02-19T00:41:41.366Z"},"accession":"S-EPMC9397655","cross_references":{"pubmed":["35758326"],"doi":["10.1093/stcltm/szac041"]}}